Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 9, 2023, the Board of Directors (the "Board") of Enfusion, Inc. (the "Company") unanimously appointed Michael Spellacy to the Board to fill an existing vacancy on the Board created by the resignation of Tarek Hammoud. In addition to his appointment to the Board, Mr. Spellacy will serve as the Chair of the Board. Mr. Spellacy will be a Class II Director and will serve on the Board until the Company's 2023 Annual Meeting of Stockholders, and until his successor is duly elected and qualified or until his earlier resignation or removal. His committee assignments will be determined at a later date.

In connection with its appointment of Mr. Spellacy, the Company amended its Non-Employee Director Compensation Policy to (1) provide an additional retainer payable to the Chair in the amount of $150,000 per year through the 2025 fiscal year, after which it will be $50,000 per year, and (2) provide that the one-time restricted stock unit award provided to new Board members would, for the Company's initial Chair, be equal in value to $250,000. The Company did not enter into any other special arrangements with Mr. Spellacy other than customary Board compensation arrangements.

In connection with Mr. Spellacy's appointment as Board Chair, Kathleen DeRose has stepped down as Interim Chair of the Board, effective January 9, 2023.

Item 7.01 - Regulation FD Disclosure.

On January 11, 2023, the Company issued a press release announcing the appointment of Mr. Spellacy to its Board. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits.

(d) The following exhibits are being filed herewith:



Exhibit No.    Description

99.1             Press Release issued by the Company on January 11, 2023, furnished
               herewith.
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses